Aviva PLC decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 41,648 shares of the company’s stock after selling 1,668 shares during the quarter. Aviva PLC’s holdings in IDEXX Laboratories were worth $10,398,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in IDXX. Dimensional Fund Advisors LP lifted its stake in IDEXX Laboratories by 0.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 325,614 shares of the company’s stock valued at $81,290,000 after acquiring an additional 1,311 shares in the last quarter. Panagora Asset Management Inc. lifted its stake in IDEXX Laboratories by 90.7% during the 3rd quarter. Panagora Asset Management Inc. now owns 262,281 shares of the company’s stock valued at $65,481,000 after acquiring an additional 124,742 shares in the last quarter. Carillon Tower Advisers Inc. lifted its stake in IDEXX Laboratories by 21.4% during the 3rd quarter. Carillon Tower Advisers Inc. now owns 329,240 shares of the company’s stock valued at $82,198,000 after acquiring an additional 57,982 shares in the last quarter. D.A. Davidson & CO. bought a new position in IDEXX Laboratories during the 3rd quarter valued at $233,000. Finally, Korea Investment CORP lifted its stake in IDEXX Laboratories by 27.3% during the 3rd quarter. Korea Investment CORP now owns 133,720 shares of the company’s stock valued at $33,385,000 after acquiring an additional 28,707 shares in the last quarter. 91.71% of the stock is owned by institutional investors.
Several brokerages have weighed in on IDXX. Canaccord Genuity dropped their price objective on IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Monday, November 5th. Bank of America dropped their price objective on IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, November 2nd. Credit Suisse Group raised their price objective on IDEXX Laboratories from $255.00 to $259.00 and gave the company an “outperform” rating in a research note on Friday, August 17th. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, August 6th. Finally, BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. IDEXX Laboratories currently has a consensus rating of “Buy” and an average target price of $252.33.
In other news, Director Rebecca M. Henderson sold 3,504 shares of IDEXX Laboratories stock in a transaction on Tuesday, November 27th. The stock was sold at an average price of $194.92, for a total transaction of $682,999.68. Following the sale, the director now directly owns 22,200 shares in the company, valued at approximately $4,327,224. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jacqueline Studer sold 3,313 shares of IDEXX Laboratories stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $201.27, for a total value of $666,807.51. The disclosure for this sale can be found here. Insiders own 2.56% of the company’s stock.
NASDAQ IDXX opened at $203.76 on Monday. The firm has a market cap of $17.57 billion, a PE ratio of 62.12, a price-to-earnings-growth ratio of 2.59 and a beta of 0.82. IDEXX Laboratories, Inc. has a one year low of $151.74 and a one year high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, November 1st. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. The company had revenue of $545.00 million for the quarter, compared to analysts’ expectations of $545.66 million. IDEXX Laboratories had a negative return on equity of 994.76% and a net margin of 15.19%. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.76 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 4.19 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “IDEXX Laboratories, Inc. (IDXX) Stake Lowered by Aviva PLC” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/12/03/idexx-laboratories-inc-idxx-stake-lowered-by-aviva-plc.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Article: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.